Skip to search formSkip to main contentSkip to account menu

Ad-ISF35

Known as: Ad-CD154 ISF35, Ad-CD40L ISF35 
A replication-defective adenovirus vector (Ad-ISF35), which encodes a membrane-stabilized, chimeric human-mouse CD40 binding protein (CD40 ligand… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53…
6528 Background: CLL cells with del(17p) typically have loss of functional p53, rendering them refractory to chemotherapeutic… 
2010
2010
Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.
Abstract 1476 Ad-ISF35 is a replication-defective adenovirus (Ad) vector that encodes ISF35, which is a potent immuno-stimulatory… 
2009
2009
Phase I study of intranodal direct injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with chronic lymphocytic leukemia.
3003 Background: Transduction of chronic lymphocytic leukemia (CLL) cells with replication-defective adenovirus (Ad) encoding a… 
2009
2009
Ad-ISF35-transduced autologous cells promote in vitro and in vivo chemosensitization in patients with 17p-/P53-defective chronic lymphocytic leukemia.
e14552 Background: Transduction of chronic lymphocytic leukemia (CLL) cells with a replication-defective adenovirus (Ad) encoding… 
2007
2007
Inhibition des Tumorwachstums von etablierten HCC-Tumoren und Rezidivprophylaxe durch intratumorale Behandlung mit CD40L-exprimierenden dendritischen Zellen in vivo
Einleitung: Dendritische Zellen (DC) konnen spezifische T-Zellen gegen Tumorantigene stark stimulieren. Ihr Einsatz gegen das HCC…